Clinical trial
ALD-301 for Critical Limb Ischemia, Randomized Trial
NCT00392509 · Aldagen, Industry · Completed
Key facts
| NCT number | NCT00392509 |
|---|---|
| Title | ALD-301 for Critical Limb Ischemia, Randomized Trial |
| Official title | A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease |
| Acronym | CLI-001 |
| Lead sponsor | Aldagen, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease |
| Intervention type | Procedure |
| Interventions | ALDH-br bone marrow cells vs. mononuclear bone marrow cells |
| Enrollment | 20 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Oct 26, 2006 |
| Last update posted | May 14, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: